Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 8, Issue 1, 2001, Pages 1-18

  Hu, K Q ^a   Vierling, J M ^b   Redeker, A G ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b MAX PLANCK INSTITUTE FOR ORNITHOLOGY   (Germany)

Author keywords

Hepatitis C virus; Immune response; Interferon therapy; Treatment of chronic hepatitis C; Viral level; Viral quasispecies

Indexed keywords

ALPHAN1 INTERFERON; AMANTADINE; CONSENSUS INTERFERON; PEGINTERFERON; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOTHERAPY; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS MUTATION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RNA, VIRAL;

EID: 0035150725     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2001.00253.x     Document Type: Review

References (226)

1. Epidemiology of hepatitis C
2. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
3. Natural history of hepatitis C
4. Hepatitis C: The clinical spectrum of disease
5. Clinical outcomes after transfusion-associated hepatitis C
6. Hepatitis C and hepatocellular carcinoma
7. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan
8. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in Europe patients with cirrhosis type C
9. The long-term clinical outcomes of patients with HCV-related compensated cirrhosis and history of parenteral exposure
10. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
11. Randomised, double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C
12. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
13. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
14. Meta-analysis of interferon randomized trials in thr treatment of viral hepatitis C: Effects of dose and duration
15. Therapy of hepatitis C: Overview
16. 10-Year follow-up after interferon-α therapy for chronic hepatitis C
17. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
18. Hepatitis C viral dynamics in vivo and antiviral efficacy of interferon-a therapy
19. The molecular biology of hepatitis viruses
20. The molecular virology of hepatitis C
21. Comparison of fulllength sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitution in the NS5a region
22. Mutation in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
23. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
24. Variability of hepatitis C virus
25. Interferon in host defense
26. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons
27. JAK-STAT pathway and transcriptional activation to interferon and other extracellular signaling proteins
28. Interferon-activated signal transduction to the nucleus
29. Cellular response to interferons and other cytokines: The JAK-STAT paradigm
30. Expression of hepatitis C virus proteins inhibits signal transduction through the JAK-STAT pathway
31. Interferon induced proteins and anti-viral actions
32. Evidence for a deficiency of interferon response in mononuclear cells from hepatitis C viremic patients
33. Mechanism of interferon action. Phosphorylation of protein synthesis initiation factor eIF-2 in interferon treated cells by a ribosome associated kinase processing site with specificity similar to heroin-regulated rabbit reticulocyte kinase
34. Immunologic mechanisms of hepatobiliary injury
35. Effects of interferon on intrahepatic human leukocyte antigens and lymphocytes subsets in patients with chronic hepatitis B and C
36. HLA class I antigens on the hapatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection
37. Acute hepatitis induced by α-interferon, associated with viral clearance, in chronic hepatitis C
38. Dynamics of hepatitis C viremia following interferon-α administration
39. Viral factors affecting outcomes of hepatitis C virus infection
40. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
41. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon
42. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
43. Chronic hepatitis C. The viral load per liver cell before treatment as a new marker to predict long-term response to IFN-α therapy
44. Hepatitis C serotype and response to interferon therapy
45. The changes in quantitative HCV RNA titers during interferon alpha 2b therapy in patient with chronic hepatitis C infection
46. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C
47. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection
48. Detection of hepatitis C virus by polymerase chain reaction and response to interferon therapy: Relationship to genotypes of hepatitis C virus
49. Factors predictive of response to interferon-α therapy in hepatitis C virus infection
50. A statistical analysis of predictive factors of response to interferon alfa in patients with chronic hepatitis C
51. Clinical relevance of hepatitis C virus geno-types
52. Correlation between virus genotype and chronicity rate in acute hepatitis C
53. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: Relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma
54. Differences in viral kinetics between HCV genotype 1 versus 2 or 3 may explain differences in treatment response
55. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients
56. Immune responses to the hepatitis C virus NS4A protein are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex
57. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution
58. Biological significance of viral quasispecies
59. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by singlestrand conformation polymorphism
60. Clinical implication of viral quasispecies heterogeneity in chronic hepatitis C
61. Evolution of hypervariable region I of hepatitis C virus in primary infection
62. Dynamics of hypervariable region I variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease
63. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection
64. Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy
65. Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C
66. The clinical significance of changes in genetic heterogeneity of the hypervariable region I in chronic hepatitis C with interferon therapy
67. The stage of chronic hepatitis C and the type of response to interferon therapy are not related with hepatitis C virus (HCV) genotype 1b quasispecies complexity
68. Secondary structure of the hepatitis C virus 5′ untranslated region and efficacy of interferon therapy for chronic hepatitis C
69. Nucleotide sequence variation in the internal ribosome entry site of hepatitis C virus-1b: No association with efficacy of interferon therapy or serum HCV-RNA level
70. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa
71. Variation in the hepatitis C virus NS5A region in relation to hypervariable region I heterogeneity during interferon treatment
72. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
73. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes
74. The 'interferon determining region' of hepatitis C virus is a stable sequence element
75. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa
76. Mutation in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection
77. Sequence analysis of hepatitis C virus subtype 1b NS5A gene segment from patients treated with human leukocyte-derived interferon alfa-N3
78. Analysis of genotypes and amino acid residues 2209-2248 of the NS5A region of hepatitis C virus in relation to response to interferon-β therapy
79. Mutation of hepatitis C virus 1b NS5A 2209-2248. Amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients
80. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
81. HCV NS5A mutations in Europeans infected by genotype 1b
82. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
83. Long-term response to interferon alpha is unrelated to 'interferon sensitivity determining region' variability in patients with chronic hepatitis C virus-1b infection
84. Improved correlation between multiple mutations within the NS5A region and virological response in Europeans patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
85. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?
86. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase
87. Repression of the PKR protein kinase by the NS5A protein of HCV 1b isolates and response to IFN therapy in French patients with chronic hepatitis C
88. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance
89. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
90. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication
91. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon
92. Hepatitis C virus NS 5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response
93. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations
94. Correlation between interferon response in patients with chronic hepatitis C and the protein kinase (PKR) binding site in HCV NS5A
95. Prospective characterization of full-length HCV NS5A quasispecies before induction and combination antiviral therapy
96. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
97. Hepatitis C virus, the E2 envelope protein, and α-interferon resistance
98. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A
99. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein
100. The amino terminal deletion mutants of hepatitis C virus nonstructural protein NS5A function as trancriptional activators in yeast
101. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator
102. Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: Relation to viral genotype, cryoglobulinemia and response to interferon
103. Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection
104. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and putative interferon sensitivity-determining region during interferon therapy and natural infection
105. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
106. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
107. Natural history of liver fibrosis progression in patients with chronic hepatitis C
108. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection
109. Radial difference in responses to therapy with interferon in chronic hepatitis C
110. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steotosis
111. Clinical and histologic predictors of response to interferon-a in patients with chronic hepatitis C viral infection
112. + T cells
113. The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell response
114. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in person with chronic hepatitis
115. Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in northern European Caucasoids
116. MHC class II genes influence susceptibility to chronic hepatitis C
117. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus
118. Genes of the major histocompatibility complex class II influence the outcomes of hepatitis C virus infection
119. HLA class II favors clearance of HCV infection and progression of the chronic liver damage
120. HLA typing in chronic type B, D and C hepatitis
121. HLA status and severity and progression of chronic hepatitis C
122. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease
123. The effect of HLA heplotype on the interferon response in patients with chronic hepatitis C
124. HLA-DR alleles predictive for nonresponsiveness to interferon α treatment in chronic hepatitis C infection
125. MHC class II and the outcomes of HCV infection
126. Pathogenesis of chronic hepatitis C, immunological features of hepatic injury and viral persistence
127. + T cells: Do they help or damage?
128. Hepatitis C viral infection in the immunosupressed patient
129. Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection
130. Different clinical behaviors of acute hepatitis C infection are associated with different vigor of anti-viral cell-mediated immune response
131. + T-cell response in acute hepatitis C
132. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection
133. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
134. Hepatitis C virus variants circulating cytotoxic T lymphocyte activity as a mechanism of chronicity
135. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
136. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection
137. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C
138. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C
139. Lymphoproliferative responses to hepatitis C virus core, E1, E2, NS3 in patients with chronic hepatitis C infection treated with interferon alfa
140. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies
141. The cellular immune responses induced in the follow-up of interferon-α treated patients with chronic hepatitis C may determine the therapy outcome
142. Lack of protective immunity against reinfection with hepatitis C virus
143. Limited humoral immunity in hepatitis C virus infection
144. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation
145. Immune treatment of HCV infection: Passive transfer of anti-HCV in acutely infected chimpanzees
146. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C
147. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: Relation to viral loads and response to interferon
148. Cytokines and the liver
149. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C chronicity
150. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines
151. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and C virus infections
152. Intracellular detection of cytokines in CD4 T cell of chronic hepatitis C. TH1/TH2 imbalance reflects disease activity
153. Cytokine profile defines different responses to interferon-α treatment in chronic hepatitis C virus infection
154. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa
155. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver
156. Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C virus infection
157. IFN-alpha recepter mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy
158. Immunohistochemical analysis of hepatitic interferon alpha-beta receptor level: Relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C
159. Apoptosis and viral hepatitis
160. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein
161. Hepatitis C virus core protein binds to the cytoplamic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis
162. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein
163. Factors predictive of a beneficial response to therapy of hepatitis C
164. Detection of replicative intermediates of hepatitis C viral RNA in liver and in serum of patients with chronic hepatitis C
165. Direct detection of circulating hepatitis C virus RNA using probes from the 5′ untranslated region
166. Negative strand of hepatitis C virus RNA in the liver of patients with chronic hepatitis C after interferon treatment
167. Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma
168. Genetic diversity and tissue compartmentalization of the hepatititis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients
169. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells
170. Hepatitis C virus RNA in plasma and blood mononuclear cells in patients with chronic hepatitis C treated with alpha-interferon
171. Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells
172. Therapy of hepatitis C patients with cirrhosis
173. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis
174. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-α therapy for chronic hepatitis C virus infection
175. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C
176. The effect of interferon on the liver in chronic hepatitis C. A quantitative evaluation of histology by meta-analysis
177. Efficacy of interferon treatment for patients with chronic hepatitis C. Comparison of response in cirrhotics, bridging fibrotics, or nonfibrotics
178. Therapy of hepatitis C. Patients with normal aminotransferase levels
179. Management of the asymptomatic HCV carrier with normal ALT levels
180. Interferon alfa treatment of HCV RNA carriers with persistent normal transaminase levels: A pilot randomized controlled study
181. Treatment of mild chronic hepatitis C with interferon-a 2b: Results of a muticentric randomized study
182. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels
183. A phase II pilot study for the treatment of HCV RNA positive blood donors with minimal or mild chronic hepatitis (CH)
184. Iron and chronic viral hepatitis
185. Therapy of hepatitis C. Other options
186. Iron overload and response to α-interferon in chronic hepatitis C
187. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C
188. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron
189. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C
190. Therapy of hepatitis C: Consensus interferon trials
191. Re-treatment of chronic C with consensus interferon
192. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial
193. Side effects of alpha interferon in chronic hepatitis C
194. Antibodies to Interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-2a therapy
195. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C
196. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
197. Viral kinetics in HCV genotype 1: Is the second phase of viral decline dose dependent?
198. Effects of interferon alfaco-1 (Infergen) on the viral kinetics of hepatitis C virus
199. Therapy of hepatitis C: Re-treatment with alpha interferon
200. A comparison of three interferon alfa-2b regiments for the long-term treatment of chronic non-A, non-B hepatitis
201. Better efficacy of a 12-month interferon alfa-ab retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial
202. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C. Results of a multicenter randomized trial
203. Dose increase augments response rate to interferon-a in chronic hepatitis C
204. Daily high-dose interferon suppresses viremia in patients with chronic hepatitis C without a previous sustained response to standard treatment
205. HCV viral kinetics analysis of daily vs BID induction interferon in genotype 1 infection
206. A randomized controlled trial of daily vs three times weekly interferon-α-2A in patients with chronic HCV and either elevated or persistently normal ALT
207. High dose induction therapy with alpha interferon is effective in patients with high hepatitis C viral load
208. High-dose induction with interferon alpha 2b is safe and efficacious in interferon relapsers and nonresponders with chronic hepatitis C
209. Comparison between a personalized treatment and a standard interferon alpha therapy for chronic hepatitis C
210. Effect of ribavirin on viral load and quasispecies distribution in patients infected with hepatitis C virus
211. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes
212. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile
213. Direct antiviral activity of ribavirin: Hepatitis C virus NS5B polymease incorporates ribavirin triphosphate into nascent RNA products
214. Amantadine hydrochloride decreases serum ALT activity without effect on serum HCV RNA in chronic hepatitis C patients
215. Randomised double-blind, placebo-controlled trial of interferon-alfa with and without amantadine as initial treatment for chronic hepatitis C
216. Interferon α-2b-ribavirin vs interferon α-2b-amantidine combination in chronic hepatitis C; analysis of a randomized, double-blind trial
217. Interferon alfa-2a in combination with ribavirin and amnatidine (triple therapy) in hepatitis C patients with previous non-response or relapse to interferon alfa and ribavirin combination therapy
218. The pharmacokinetics of pegylated-40k interferon alfa-2a (PGE-IFN) in chronic hepatitis C (CHC) patients with cirrhosis
219. PEG-interferon-α2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data
220. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alfa-2a (PEG) vs standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C
221. Combination therapy with peginterferon α-2A (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC): A phase II open-label study
222. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for treatment of chronic hepatitis C
223. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
224. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C
225. Estimates of the cost-effectiveness of a single course of interferon-22b in patients with histologically mild chronic hepatitis C
226. Pretreatment evaluation of chronic hepatitis C. Risks, benefits, and costs